Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials

Abstract

Introduction: Hypertension is one of the most common cardiovascular diseases, and the prevalence of hypertension continues to rise across the globe. National and international guidelines recommend angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, and beta-blockers for the management of hypertension. CCBs are among the most used antihypertensive medications and Cilnidipine is a newer dihydropyridine CCB shown to have a prolonged antihypertensive property. Objective: This meta-analysis of comparative randomized and non-randomized clinical trials evaluated the effect of Cilnidipine monotherapy or combination therapy on systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate (PR) over 48 weeks of therapy. Study design: PubMed (MEDLINE) and Google scholar databases were searched to identify studies designed to evaluate the effects of Cilnidipine in the treatment of hypertensive patients. The study criteria for inclusion into the meta-analysis were all prospective, randomized, and non-randomized clinical studies published till March 2021, studies published in a peer-reviewed journal, the inclusion of patients with hypertension, assessment of blood pressure and heart rate, and a follow-up of four weeks or longer. The initial search identified 82 potential articles; of these, 24 met the inclusion criteria. Studies with <4 weeks treatment period and those not having a CCB were excluded. Outcomes: Change in SBP, DBP, and PR from baseline at the end of therapy compared between the Cilnidipine and other CCB's. Results: Cilnidipine caused a significant reduction (p<0.05) in SBP, DBP, and PR at end of therapy, whereas the reduction in SBP, DBP, and PR with Cilnidipine was similar to other CCB's (p>0.05). The results of this meta-analysis revealed that there were no significant differences in the efficacy in the treatment of hypertensive patients with Cilnidipine and the other therapies. Conclusion: Cilnidipine has similar anti-hypertensive effects compared with other first-line antihypertensive drugs commonly used in practice. We recommend Cilnidipine as a novel first-line CCB for the management of hypertension either as a monotherapy or as a combination therapy.

A Randomized, Open-Label, Two-way Crossover Bioequivalence Study of Cilacar Tablet Compared with Atelec Tablet in Healthy Volunteers Under Fasting Condition

“…It is postulated that Cilnidipine exhibits a high protein binding of 98% along with a high volume of distribution, which prolongs the duration of action of the molecule. A 2021 metaanalysis presented by Chakraborty R et al 7 concluded that Cilnidipine significantly reduced systolic blood pressure, diastolic blood pressure, and pulse rate in hypertensive patients.…”

“…A recent meta-analysis concludes Cilnidipine to be the firstline CCB for the management of hypertension either as a monotherapy or as a combination therapy. 7 Cilnidipine is approved for use in Japan under the brand name, Atelec ® by Ajinomoto Pharmaceuticals.…”